what are the benefits of microdosing glp 1 Should You Microdose a GLP-1? and Risks Microdosing GLP-1: A New Approach

It tells us there is no large effect, not that there is no effect at all

As a result, those with endocrine system conditions are not advised to take Ozempic or Wegovy

Nearly 25% of the population in western countries have NAFLD and up to 6.5% fulfill the criteria of NASH ( NAFLD is considered the hepatic manifestation of metabolic syndrome ( No pharmacological therapies are approved for the treatment of NAFLD and lifestyle changes focusing on caloric restriction and weight loss constitute the general treatment recommendations

Puri A, Mohite P, Maitra S, Subramaniyan V, Kumarasamy V, Uti DE, Sayed AA, El-Demerdash FM, Algahtani M, El-kott AF, Shati AA, Albaik M, Abdel-Daim MM, Atangwho IJ